Business, energy, technology, markets and global industry news from Business News Today

lacutamab

PharmaDeviceNews lacutamab
Editorial infographic highlighting Innate Pharma’s November 5, 2026 update, featuring a clinical research laboratory, immunotherapy imagery, a calendar, and key developments involving IPH4502, the Sobi partnership and monalizumab.
Pharma & Biotech

Innate Pharma faces a crucial November update. Can its ADC pipeline and Sobi deal strengthen its position?

Innate Pharma plans its November 5 update as IPH4502 data, the Sobi partnership and monalizumab milestones approach. Key clinical questions remain.

Read More
Innate Pharma’s lacutamab partnership with Sobi could unlock the TELLOMAK-3 Phase 3 trial and a potential accelerated approval pathway in T-cell lymphoma, with the licensing agreement carrying up to $580 million in potential value. Representative image.
Pharma & Biotech

What Sobi’s lacutamab licensing deal means for Innate Pharma and TELLOMAK-3

Innate Pharma’s Sobi deal brings $75m upfront and could unlock TELLOMAK-3, accelerated approval and global commercialization of lacutamab.

Read More
Representative image of a biotech conference setting as Innate Pharma heads to the Kempen Life Sciences Conference, where investors are expected to assess the outlook for IPH4502, lacutamab, and monalizumab within the company’s immuno-oncology pipeline.
Pharma & Biotech

What Innate Pharma’s Kempen conference participation reveals about its 2026 biotech strategy

Innate Pharma heads to Kempen as investors assess its oncology pipeline, partnering outlook, and next catalysts. Read the full analysis.

Read More